 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
152 News |  |
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, mevrometostat (PF-06821497) / Pfizer
New P3 trial, Combination therapy, Metastases: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (clinicaltrials.gov) - Aug 12, 2024
P3, N=600, Not yet recruiting, Sponsor: Pfizer
- mevrometostat (PF-06821497) / Pfizer
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC). (Hall A; Poster Bd #: 467) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2243;
P1
This is an open-label, phase 1/2 study of M (orally, 150-1250 mg twice daily) + E (160 mg daily) in adult pts with CRPC who had received prior abiraterone (A) and/or E and had evidence of cancer progression per Prostate Cancer Working Group 3 (PCWG3) criteria at entry... M+E shows promising activity in both post-A (without E) and post-E (
- || PF-06821497 / Pfizer
Trial completion: A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (clinicaltrials.gov) - Jul 12, 2023
P1, N=18, Completed, Sponsor: Pfizer
M+E shows promising activity in both post-A (without E) and post-E ( Active, not recruiting --> Completed
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - May 23, 2023
P1, N=267, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Nov 2025
- || PF-06821497 / Pfizer
Enrollment closed: A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (clinicaltrials.gov) - May 19, 2023
P1, N=18, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Nov 2025 Recruiting --> Active, not recruiting
- || mevrometostat (PF-06821497) / Pfizer
Enrollment change, Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - May 3, 2023
P1, N=267, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Jan 2025 --> Apr 2025 | N=185 --> 267
- || mevrometostat (PF-06821497) / Pfizer
Enrollment change, Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Apr 19, 2023
P1, N=185, Recruiting, Sponsor: Pfizer
Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Jan 2025 --> Apr 2025 | N=185 --> 267 N=267 --> 185 | Trial completion date: Sep 2025 --> Jan 2025 | Trial primary completion date: Sep 2025 --> Jan 2025
- |||||| PF-06821497 / Pfizer
Clinical: In recent #HematologyNews, study findings show EZH2 inhibitor PF-06821497 yielded safe and effective results among patients with #FollicularLymphoma. Click the link to learn more about Dr Schweizer's research! @MikeSchweizerMD https://t.co/PKwUiJFAvq (Twitter) - Mar 30, 2023
- || PF-06821497 / Pfizer
Enrollment open: A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (clinicaltrials.gov) - Mar 24, 2023
P1, N=18, Recruiting, Sponsor: Pfizer
N=267 --> 185 | Trial completion date: Sep 2025 --> Jan 2025 | Trial primary completion date: Sep 2025 --> Jan 2025 Not yet recruiting --> Recruiting
- || PF-06821497 / Pfizer
New P1 trial: A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (clinicaltrials.gov) - Mar 14, 2023
P1, N=18, Not yet recruiting, Sponsor: Pfizer
- || mevrometostat (PF-06821497) / Pfizer
Enrollment change: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Feb 24, 2023
P1, N=267, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=185 --> 267
- PF-06821497 / Pfizer
A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC). (Available On Demand; Poster Board No.Q4) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_169;
P1, P2
Part 2B compares the safety and efficacy of twice-daily PF-06821497 in combination with E (160 mg daily) (treatment arm) versus E monotherapy (control arm) administered continuously in patients with mCRPC previously treated with abiraterone...Secondary objectives include further evaluation of anti-tumor activity of PF-06821497, and assessment of single and multiple dose PK when given in combination with E. The impact of PF-06821497 in combination with E and of E alone in men with mCRPC on patient reported outcomes will also be assessed. Clinical trial information: NCT03460977.
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Aug 5, 2022
P1, N=185, Recruiting, Sponsor: Pfizer
Clinical trial information: NCT03460977. Trial completion date: Nov 2024 --> Jul 2025 | Trial primary completion date: Nov 2024 --> Jul 2025
- PF-06821497 / Pfizer
Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_1965;
P1
provided enzalutamide for this study...All Part 2A pts with CRPC (n=32) had prior abiraterone and/or E; among evaluable pts (n=28), there were 4 objective responses (14.3%) (1 complete response [prior E] and 3 PRs [E naïve])...Conclusions PF-06821497 had a manageable safety profile, with evidence of EZH2 PD inhibition and durable objective tumor responses in pts with mCRPC and FL. A randomized trial in mCRPC is ongoing.
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Jun 8, 2022
P1, N=185, Recruiting, Sponsor: Pfizer
A randomized trial in mCRPC is ongoing. Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: May 2024 --> Nov 2024
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Jan 28, 2022
P1, N=185, Recruiting, Sponsor: Pfizer
Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: May 2024 --> Nov 2024 Trial completion date: Dec 2024 --> May 2024 | Trial primary completion date: Dec 2024 --> May 2024
- PF-06821497 / Pfizer
Process Chemistry Development for the EZH2 Inhibitor PF-06821497 (Room 1B (San Diego Convention Center)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_9287;
Trial completion date: Dec 2024 --> May 2024 | Trial primary completion date: Dec 2024 --> May 2024 Development of new synthetic routes to the Zeste Homolog 2 (EZH2) Inhibitor PF-06821497 will be described.
- PF-06821497 / Pfizer
Bidirectional synthetic enablement of the EZH2 candidate PF-06821497 (Room 6C) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_2129;
Thus, acetate performed better than carbonate and acetonitrile performed better than methanol. This new process installed the secondary alcohol early in the synthesis and oxidation followed by asymmetric reduction using a keto-reductase, provided a more efficient process for isolating the secondary alcohol with a high yield and >99% ee.
- | Zolinza (vorinostat) / Merck (MSD), Tazverik (tazemetostat) / Epizyme, Eisai, ONC201 / Chimerix
Journal: EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. (Pubmed Central) - Jan 18, 2022
Although synergy was observed with ONC201 and vorinostat, there was no significant increase in H3K27 acetylation in cell lines including DIPG as compared to vorinostat alone, and in some cases the acetylation was less than vorinostat alone at 72 H. H3K27 methylation reduction correlated with synergy from combinations of either EPZ-6438 or vorinostat with ONC201 or triple combination. Our findings provide a rationale for combination of ONC201 and epigenetic modulators including triple therapy for in vivo and clinical testing in treatment of human malignancies including brain tumors and DIPG.
- || mevrometostat (PF-06821497) / Pfizer
Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Sep 26, 2021
P1, N=185, Recruiting, Sponsor: Pfizer
Our findings provide a rationale for combination of ONC201 and epigenetic modulators including triple therapy for in vivo and clinical testing in treatment of human malignancies including brain tumors and DIPG. Trial primary completion date: Jul 2023 --> Dec 2024
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Mar 22, 2021
P1, N=172, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jul 2023 --> Dec 2024 Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
- ONC201 / Chimerix
[VIRTUAL] The integrated stress response (ISR) is involved in the synergistic combinatorial efficacy of ONC201 and epigenetic modulators in brain tumor cell lines () - Mar 13, 2021 - Abstract #AACR2021AACR_4228;
EPZ-6438 or PF-06821497 decreased H3K27 tri-methylation. Our study results unravel potent synergy between ONC201 and EZH2i, highlight the role of ISR in the synergy, and provide further insights into the role of H3K27me3 in ONC201 drug sensitivity.
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Oct 30, 2020
P1, N=172, Recruiting, Sponsor: Pfizer
Our study results unravel potent synergy between ONC201 and EZH2i, highlight the role of ISR in the synergy, and provide further insights into the role of H3K27me3 in ONC201 drug sensitivity. Trial completion date: Apr 2023 --> Nov 2022 | Trial primary completion date: Apr 2023 --> Nov 2022
- || PF-06821497 / Pfizer
PK/PD data, Journal: Translational Pharmacokinetic-Pharmacodynamic Modeling for An Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2. (Pubmed Central) - Sep 9, 2020
The modeling results suggest that >70% H3K27me3 inhibition would be required for tumor stasis (i.e., 100% tumor growth inhibition). Accordingly, we would propose that an EC estimate for H3K27me3 inhibition could be considered a minimum target efficacious concentration of PF06821497 in cancer patients.
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Jun 17, 2020
P1, N=172, Recruiting, Sponsor: Pfizer
Accordingly, we would propose that an EC estimate for H3K27me3 inhibition could be considered a minimum target efficacious concentration of PF06821497 in cancer patients. Trial completion date: Apr 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Mar 2023
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - May 7, 2020
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Apr 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Mar 2023 Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Apr 2022
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Feb 19, 2020
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Apr 2022 Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021
- ||||| PF-06821497 / Pfizer, Tazverik (tazemetostat) / Epizyme, Eisai
Clinical, FDA event: The FDA approval of #EZH2 inhibitor #tazemetostat is a milestone for epigentic drug discovery (despite the controversy about its clinical value). EZH2 inhibitor design is also a poster child for the value of optimizing conformations @JMedChem @EpizymeRx @CPI_epigenetics @pfizer (Twitter) - Feb 9, 2020
- |||| PF-06821497 / Pfizer
Histone Lysine N Methyltransferase EZH2, Pipeline Review, H2 2019 - Domainex Ltd, Kainos Medicine Inc, Epizyme Inc & Pfizer Inc - https://t.co/guyiBzPH8C https://t.co/0iFMlQcEZp (Twitter) - Jan 16, 2020
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Dec 17, 2019
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Jul 2021 --> Oct 2021 | Trial primary completion date: Jul 2021 --> Oct 2021 Trial completion date: Dec 2023 --> Sep 2021 | Trial primary completion date: Dec 2023 --> Sep 2021
- | mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Oct 24, 2019
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Dec 2023 --> Sep 2021 | Trial primary completion date: Dec 2023 --> Sep 2021 Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023
- PF-06821497 / Pfizer
Inhibition of EZH2 enhances tumor immunogenicity through diversification of tumor antigen presentation (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1043;
Our data illustrate the potential for targeting EZH2 to increase the immunogenicity of tumors through relieving epigenetic suppression of tumor antigen presentation machinery and silenced neoantigens. As EZH2 inhibitors are currently under clinical investigation, targeting EZH2 represents a promising combination approach with checkpoint inhibitors to elicit responses in poorly immunogenic tumors.
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Jul 2, 2019
P1, N=172, Recruiting, Sponsor: Pfizer
As EZH2 inhibitors are currently under clinical investigation, targeting EZH2 represents a promising combination approach with checkpoint inhibitors to elicit responses in poorly immunogenic tumors. Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Dec 17, 2018
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Trial completion date: Feb 2023 --> May 2023 | Trial primary completion date: Feb 2023 --> May 2023
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Aug 29, 2018
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Feb 2023 --> May 2023 | Trial primary completion date: Feb 2023 --> May 2023 Trial completion date: Oct 2023 --> Feb 2023 | Trial primary completion date: Oct 2023 --> Feb 2023
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Aug 9, 2018
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Oct 2023 --> Feb 2023 | Trial primary completion date: Oct 2023 --> Feb 2023 Trial completion date: Nov 2021 --> Oct 2023 | Trial primary completion date: Nov 2021 --> Oct 2023
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Jul 5, 2018
P1, N=172, Recruiting, Sponsor: Pfizer
Trial completion date: Nov 2021 --> Oct 2023 | Trial primary completion date: Nov 2021 --> Oct 2023 Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2020 --> Nov 2021
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Apr 10, 2018
P1, N=172, Not yet recruiting, Sponsor: Pfizer
Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2020 --> Nov 2021 Trial completion date: Jul 2021 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2020
- || mevrometostat (PF-06821497) / Pfizer
Trial completion date, Trial primary completion date: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Apr 7, 2018
P1, N=172, Not yet recruiting, Sponsor: Pfizer
Trial completion date: Jul 2021 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2020 Trial completion date: Nov 2021 --> Jul 2021 | Trial primary completion date: Nov 2021 --> Jul 2021
- ||| mevrometostat (PF-06821497) / Pfizer
New P1 trial: PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov) - Mar 9, 2018
P1, N=172, Not yet recruiting, Sponsor: Pfizer